- GC Cell and PT Bifarma Adiluhung announced a strategic
partnership to facilitate the entry of 'Immuncell-LC', the only
approved autologous T-cell therapy for HCC into the Indonesian
market.
YONGIN, South Korea, June 19,
2024 /PRNewswire/ -- GC Cell, a fully integrated cell
and gene therapy pioneer, is proud to announce the establishment of
an MOU for strategic partnership with Bifarma, a frontrunner in
stem cell therapy within Indonesia
with comprehensive capabilities in R&D, GMP-compliant
manufacturing, and the commercialization of cell therapies. Bifarma
is a Subsidiary of Southeast
Asia's Leading Pharmaceutical, PT Kalbe Farma Tbk.
This strategic partnership marks a significant step towards
entering the Indonesian market and expanding into the innovative
cell therapy sector, particularly to facilitate the entry of
'Immuncell-LC', the only approved autologous T-cell therapy for
liver cancer surgery in Korea. The MOU also includes discussions on
technology transfer and broad cooperation on the development of
additional NK cell therapy pipelines.
Furthermore, GC Cell recently unveiled its Blueprint 2.0
strategy, emphasizing a company-wide strategic shift towards future
growth drivers. A pivotal component of this strategy is the global
market entry of its proprietary cell therapy products,
Immuncell-LC, Korea's pioneering cell therapy, along with securing
the foundation for NK cell therapy pipelines across the
Asia-Pacific region.
Indonesia, known for its large
population and robust growth rate coupled with the advent of
universal healthcare, presents a promising market for autologous
cell therapies. Such therapies are increasingly accessible through
medical procedures that are supported by substantial clinical data,
similar to those in Japan. Through
this strategic partnership with Bifarma and leveraging the Kalbe
Group's extensive local infrastructure, including cold chain
logistics and a broad hospital network, GC Cell anticipates the
accelerated launch of its Immuncell-LC beyond Korea.
James Park, CEO of GC Cell,
commented, "This partnership is a testament to the global
recognition of our cell therapy expertise, first established in
Korea. By combining GC Cell's integrated value chain in cell and
gene therapy with Bifarma's strong market presence and capabilities
in Indonesia, we are poised to
rapidly capture a leading position in the burgeoning field of
anti-cancer cell therapies."
"We are pleased to announce that Bifarma, through our cell
therapy division ReGeniC, has entered into a MOU with GC Cell, a
pioneering biopharmaceutical company from Korea. This strategic
collaboration represents a significant milestone for both
organizations and reinforces our mission to offer advanced, safe,
and high-quality cell therapy," said Dr. Sandy Qlintang, MBiomed.,
President Director of PT Bifarma Adiluhung.
This MOU represents a significant milestone for both
organizations in their pursuit to transform patient care and
fortify their positions in the global healthcare landscape.
About GC Cell
With a core focus on cell therapy, GC Cell offers complete bio
healthcare solutions from diagnosis to treatment, and the brand's
comprehensive value chain spans R&D, production,
commercialization, and distribution.
More info: https://gccell.com//
About PT Bifarma Adiluhung
PT Bifarma Adiluhung, through its cell therapy division Regenic,
is Indonesia's first and largest
cell-based therapy provider, holding GMP certification from
Indonesia's FDA and an operating
license from Ministry of Health for clinical-grade manufacturing of
stem cells and their metabolites. Regenic services encompass
autologous and allogeneic stem cells and their derivatives, a stem
cell education center, and an R&D center focused on innovative
cell therapy products. Regenic is dedicated to advancing healthcare
through pioneering cell-based therapies to enhance the quality of
life for all individuals.
About PT Kalbe Farma Tbk
PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of
the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions
that handle a portfolio of dependable and various brands: the
prescription pharmaceutical division, the health products division
that handles over-the-counter drugs, multivitamins, and
ready-to-serve supplemental drinks, the nutritions division, and
the distribution & logistics division.
Kalbe has also developed B2B-based digital services ecosystems
for the society: EMOS and MOSTRANS. EMOS is an order management
application system that helps distribution channels perform their
stock or supply chain management actions. MOSTRANS is a B2B
transportation solution provider for the easy management and the
efficiency of transportation.
Kalbe now has more than 40 subsidiaries and 14
international-standard production facilities, supported by around
16,000 employees in 71 branches throughout Indonesia. Kalbe's shares have been listed in
Indonesia Stock Exchange/Bursa
Efek Indonesia (IDX:KLBF) since 1991. For more information, please
visit https://www.kalbe.co.id/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gc-cell-signs-an-mou-with-pt-bifarma-adiluhung-an-affiliate-of-kalbe-group-302177440.html
SOURCE GC Cell